

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
March 10, 2017**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Sciclone Pharmaceuticals, Inc.

File No. 000-19825 -CF#34129

Sciclone Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 9, 2016, as amended.

Based on representations by Sciclone Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through June 30, 2026
Exhibit 10.2	through June 30, 2026
Exhibit 10.3	through June 30, 2026
Exhibit 10.4	through June 30, 2026
Exhibit 10.5	through June 30, 2026

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary